The DuraGraft® CABG European registry is a prospective, multi-center, observational study to document clinical use of DuraGraft and associated outcomes of patients whose vascular grafts are treated with DuraGraftRead More
JUPITER, Fla., Jan. 4, 2017 -- Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced enrollment of the first subject in their DuraGraft® CABG European Registry.Read More
Somahlution is an innovation-driven global company specializing in the development and marketing of products that make a meaningful difference in healthcare. Science, quality and patients are at the heart of everything we do, and our skills and resources are concentrated on therapeutic areas where there is significant unmet clinical need and where we believe we can make the most difference. Learn more about Somahlution.
We look forward to any questions you may have. Please get in touch with us, by clicking here.